

Press Release for IPF Summit

Moerae Matrix to Present MMI-0100 Phase 1 Pharmacodynamic Data at the Inaugural 2017 Idiopathic Pulmonary Fibrosis Summit

August 21, 2017
Boston, MA

Moerae Matrix today announced that the company will present pharmacodynamic data from a Phase 1 study of MMI-0100, during the inaugural IPF Summit to be held in Boston, MA on **Monday, August 21-22, 2017**. MMI-0100 is a first-in-class inhibitor of MAPKAP Kinase 2 (MK2) and has been studied in three Phase 1 clinical trials.

During the first day of the IPF Summit, during the session, “Emerging Platforms: The Development and Validation of Diagnostic and Prognostic Biomarkers.”

Details of the presentation, which is currently scheduled to begin at approximately 12:10 PM, include:

Title: Enhancing Anti-Inflammatory Effects as Measured by Serum IL-6; Lessons learned from the development of a novel, rationally-designed cell-penetrating peptide inhibitor of MK2

- Presenter: Cynthia Lander, Chief Executive Officer, Moerae Matrix, Inc.

Synopsis

- Highlighting the role of MK2, a terminal kinase in the TGF- β /p38 kinase cascade, in inflammation and fibrosis
- Demonstrating the impact of combining a rationally designed peptide (MMI-0100), that mimics native substrates, with cell penetrant technology on target engagement
- Showcasing the ability to effectively monitor the anti-inflammatory pharmacodynamics effects through measurement of serum IL-6

About Moerae Matrix, Inc.

Moerae Matrix, Inc. is a private biopharmaceutical company leading in the development of first-in-class therapies targeting MAPKAP Kinase 2 (MK2), a terminal kinase in the TGF- β pathway that mediates inflammatory and fibrotic responses in multiple diseases with high unmet medical need and large markets.

Moerae is developing MMI-0100, an inhaled cell-permeant peptide inhibitor of MK2, for pulmonary indications including Idiopathic Pulmonary and Chronic Obstructive Pulmonary Disease. IPF is an Orphan Disease that is associated with a mortality rate of 75% at five years. COPD is the third-leading cause of death worldwide. For more information, please visit the company's website at <http://moeraematrix.com>.